



Roche Roche Group

FY2008 3Q Consolidated Financial Overview

CHUGAI PHARMACEUTICAL CO., LTD.
General Manager
Finance&Accounting Dept.
Toshiaki Itagaki

October 21, 2008

Forward-Looking Statements

This presentation may include forward-looking statements pertaining to the business and prospects of Chugai Pharmaceutical Co., Ltd. (the “Company”). These statements reflect the Company’s current analysis of existing information and trends. Actual results may differ from expectations based on risks and uncertainties that may affect the Company’s businesses.

Note: Amounts are rounded to the nearest 0.1 billion yen.
% is calculated based on amounts shown.

Financial Overview (Year on Year)

(Billion Yen)	Sep. 2007	Sep. 2008	Variance	(%)
Revenues	250.5	229.7	-20.8	-8.3
Cost of Sales	101.0	87.6	-13.4	-13.3
% of Sales	41.6%	39.0%		
Selling & Admin. Exp.	61.6	65.9	+4.3	+7.0
% of Revenues	24.6%	28.7%		
R&D Exp.	38.8	36.3	-2.5	-6.4
% of Revenues	15.5%	15.8%		
Operating Income	49.0	39.8	-9.2	-18.8
% of Revenues	19.6%	17.3%		
Recurring Profit	51.0	42.7	-8.3	-16.3
% of Revenues	20.4%	18.6%		
Net Income	30.2	30.1	-0.1	-0.3
% of Revenues	12.1%	13.1%		

	(Billion Yen)
> Revenues	- 20.8 (-8.3%)
Refer to P.4-P.5	
> Operating Income	-9.2 (-18.8%)
Refer to P.6	
> Recurring Profit	- 8.3 (-16.3%)
> Net Income	- 0.1 (-0.3%)

Foreign Exchange Rate

Average rate (Jan. 1 – Sep. 30, 2007)


119.36Yen/US\$, 237.10Yen/ £ 、 97.96Yen/CHF、 160.37Yen/€

Average rate (Jan. 1 – Sep. 30, 2008)

105.85Yen/US\$, 206.00Yen/ £ 、 100.08Yen/CHF、 160.93Yen/€

Revenues (Year on Year)

(Billion Yen)




* other operating income

<Breakdown of Revenues>


(Billion Yen)		Sep. 2007	Sep. 2008	Variance	(%)
Revenues		250.5	229.7	-20.8	-8.3
Sales		242.8	224.9	-17.9	-7.4
TAMIFLU	Ordinary Sales	5.0	1.5	-3.5	-70.0
	Govt. Stock etc.	26.8	0.2	-26.6	-99.3
	Total	31.8	1.7	-30.1	-94.7
Sales excl. TAMIFLU		211.0	223.2	+12.2	+5.8
EPOGIN		40.4	32.8	-7.6	-18.8
Others		170.6	190.4	+19.8	+11.6
Royalties and OOI		7.6	4.8	-2.8	-36.8
Overseas		26.4	25.0	-1.4	-5.3

Sales of Top Five Products (Year on Year)

(Billion Yen)



Operating Income (Year on Year)



Financial Overview (vs. Forecast)

(Billion Yen)	Revised Forecast Jul. 31	Actual Sep. 2008	Progress
Revenues	326.0	229.7	70.5%
Cost of Sales	130.0	87.6	67.4%
% of Revenues	39.9%	38.1%	
Selling & Admin Exp.	94.5	65.9	69.7%
% of Revenues	29.0%	28.7%	
R&D Exp.	53.5	36.3	67.9%
% of Revenues	16.4%	15.8%	
Operating Income	48.0	39.8	82.9%
% of Revenues	14.7%	17.3%	
Recurring Profit	49.0	42.7	87.1%
% of Revenues	15.0%	18.6%	
Net Income	33.0	30.1	91.2%
% of Revenues	10.1%	13.1%	

(Billion Yen)		Forecast (Jul 31)	Actual Sep 2008	Progress
Revenues		326.0	229.7	70.5%
TAMIFLU	Ordinary Sales	3.7	1.5	40.5%
	Govt. Stock etc.	1.3	0.2	15.4%
	Total	5.0	1.7	34.0%
Sales excl. TAMIFLU		321.0	228.0	71.0%
EPOGIN		45.2	32.8	72.6%
Others		275.8	195.2	70.8%

Overview of R&D Activities

CHUGAI PHARMACEUTICAL CO.,LTD.
Vice President
General Manager of Clinical Development Div.
Yutaka Tanaka

October 21, 2008

R&D Topics (January~April 2008)

- GC33: Started phase I study for liver cancer
- R7159(GA101): Started phase I study for non-Hodgkin's lymphoma
- NA808: Started phase I study for chronic hepatitis C

- R597 (Herceptin): Approved for modification of manufacturing process for drug substance (to use porcine derived material)
- MRA (Actemra): Received Complete Response Letter from the FDA regarding the US application for rheumatoid arthritis

Contacts:

Corporate Communications Group

Tel: +81 (0)3-3273-0881 Fax: +81 (0)3-3281-6607

e-mail: pr@chugai-pharm.co.jp

Masayuki Yamada, Seiji Shimada, Hiroshi Araki

Investor Relations Group

Tel: +81 (0)3-3273-0554 Fax: +81 (0)3-3281-6607

e-mail: ir@chugai-pharm.co.jp

Mac Uchida, Kae Maeda, Tomoko Shimizu, Yusuke Tokita